HBW 016
Alternative Names: HBW-016Latest Information Update: 28 Aug 2023
At a glance
- Originator Chengdu Hyperway Pharmaceuticals
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 28 Aug 2023 HBW 016 is available for licensing as of 28 Aug 2023. http://hyperwaypharma.com/index.php/en/cooperation.html
- 10 Jul 2023 Preclinical trials in Cancer in China (unspecified route) prior to July 2023 (Chengdu Hyperway Pharmaceuticals pipeline, July 2023)